Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech VC Funding Rises As Fewer Companies Get More Dollars

Executive Summary

Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.

Advertisement

Related Content

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Finance Watch: Happy Holidays For Flagship With A New $618m Fund
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
VCs Raise Cash For New Deals; Five Biotechs Find Funding
Biotech benefits as VC firms raise cash in Q2
Allergan buys chin fat firm Kythera for $2.1bn
Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn
BioNotebook: Second Genome/Pfizer, Merck/Agenus, Endo/Somar, Parion/Gilead, Lightstone Ventures, Kite Pharma, five IPO updates
J&J enters deal with Second Genome to study gut bacteria

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel